CLAIMS

1. Use of a checkpoint kinase 1 (CHK1) inhibitor selected from the group consisting of (R)-N-(4-(3-amino- piperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)nicotinamide; (R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)isobutyramide; (R)-N-(5-bromo-4-(3-(methylamino) piperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)nicotinamide; (R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo-[2,3-b]pyridin-3-yl)-5-methylnicotinamide; (R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide; (R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]-pyridin-3-yl)-3-methylbutanamide; and (R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]-pyridin-3-yl)-2-cyclopropylacetamide, in the manufacture of a medicament for the treatment of a patient with cancer, wherein the medicament will be for use in potentiating a DNA damaging agent in a method for treating the cancer, wherein the administration of the medicament is to follow the administration of the DNA damaging agent, wherein the medicament is to be administered in two doses, the first dose of the medicament is to be administered one day after the DNA damaging agent, and the second dose of the medicament is to be administered two days after the DNA damaging agent.

2. Use of a checkpoint kinase 1 (CHK1) inhibitor selected from the group consisting of (R)-N-(4-(3-amino-piperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)nicotinamide; (R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)isobutyramide; (R)-N-(5-bromo-4-(3-(methylamino)- piperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)nicotinamide; (R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo-[2,3-b]pyridin-3-yl)-5-methylnicotinamide; (R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide; (R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]-pyridin-3-yl)-3-methylbutanamide; and (R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]-pyridin-3-yl)-2-cyclopropylacetamide, in the manufacture of a medicament for the treatment of a patient with cancer , wherein the medicament will be for use in potentiating a DNA damaging agent in a method for treating the cancer, wherein the administration of the medicament is to follow the administration of the DNA damaging agent, wherein the medicament is to be administered in three doses, the first dose of the medicament is to be administered one day after the DNA damaging agent, the second dose of the medicament is to be administered two days after the DNA damaging agent, and the third dose of the medicament is to be administered three days after the DNA damaging agent.

3. The use according to Claim 1 or Claim 2, wherein the inhibitor is (R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)nicotinamide.

4. The use according to Claim 1 or Claim 2, wherein the inhibitor is (R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)isobutyramide.

5. The use according to Claim 1 or Claim 2, wherein the inhibitor is (R)-N-(5-bromo-4-(3-(methylamino)piperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)nicotinamide.

6. The use according to Claim 1 or Claim 2, wherein the inhibitor is (R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-methylnicotinamide.

7. The use according to Claim 1 or Claim 2, wherein the inhibitor is (R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide.

8. The use according to Claim 1 or Claim 2, wherein the inhibitor is (R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-methylbutanamide.

9. The use according to Claim 1 or Claim 2, wherein the inhibitor is (R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-cyclopropylacetamide.

10. The use according to any one of Claims 1 to 9, wherein the DNA damaging agent is selected from the group consisting of gemcitabine, irinotecan, temozolomide, capecitabine, topotecan, cisplatin, oxaliplatin, carboplatin, camptothecin, cytarabine, fluorouracil, cyclophosphamide, etoposide phosphate, teniposide, doxorubicin, daunorubicin, pemetrexed, and radiation.

11. The use according to any one of Claims 1 to 10, wherein the DNA damaging agent is selected from the group consisting of gemcitabine, irinotecan, cisplatin, oxaliplatin, carboplatin and cytarabine.

12. The use according to any one of Claims 1 to 10, wherein the DNA damaging agent is selected from the group consisting of gemcitabine, irinotecan, temozolomide, capecitabine, camptothecin, cisplatin, cytarabine, and 5-FU.

13. The use according to any one of Claims 1 to 10 or Claim 12, wherein the DNA damaging agent is selected from the group consisting of gemcitabine, irinotecan, temozolomide and capecitabine.

14. The use according to any one of Claims 1 to 13, wherein the DNA damaging agent is selected from the group consisting of gemcitabine and irinotecan.

15. The use according to any one of Claims 1 to 14, wherein the medicament is to be administered between the biologically effective dose and the maximum tolerated dose.

16. The use according to any one of Claims 1 to 15, wherein the cancer is selected from colorectal cancer (including Ras mutations), small cell lung cancer, non-small cell lung cancer (including Ras mutations), glioma, ovarian cancer, metastatic breast cancer, pancreatic cancer, hepatobiliary cancer (including hepatocellular cancer, bile duct cancer and cholangiocarcinoma), gastric cancer, testicular cancer, head and neck squamous cell carcinoma, leukemia (including acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and chronic lymphoid leukemia), lymphoma (including mantle cell lymphoma, Hodgkin’s lymphoma and non-Hodgkin’s lymphoma), and prostate cancer.